LOGIN  |  REGISTER
Recursion
Viking Therapeutics

Phreesia Sets Release Date for Fiscal Fourth Quarter and Fiscal Year 2025 Results

February 07, 2025 | Last Trade: US$24.96 0.10 0.40

ALL-REMOTE COMPANY/WILMINGTON, Del. / Feb 07, 2025 / Business Wire / Phreesia, Inc. (NYSE: PHR) (“Phreesia”) today announced that it will release its fiscal fourth quarter and fiscal year 2025 financial results after the close of market trading on Wednesday, March 12, 2025. Phreesia will issue a press release announcing its quarterly and full year results and the company’s quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal fourth quarter and fiscal year 2025 results starting at 5PM Eastern Time on the same day.

To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international participants, using conference code number 7404611, or visit the “Events & Presentations” section of ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

ABOUT PHREESIA

Phreesia is a trusted leader in patient activation, giving providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 150 million patient visits in 2023—more than 1 in 10 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page